Bio-Path Holdings, Inc., a biotechnology company, through its subsidiary, Bio-Path, Inc., develops liposomal drug delivery systems. Its drug delivery technology distributes nucleic acid drugs throughout the human body via intravenous infusion, as well as enables systemic delivery of antisense, small interfering RNA (siRNA), and small molecules for treatment of cancer. The company?s under pre-clinical development products include its lead lipid delivery RNAi drug, BP-100-1.01, that treats acute myeloid leukemia, myelodysplastic syndrome, and chronic myelogenous leukemia; and lead siRNA drug, BP-100-2.01, a targeted ovarian cancer therapeutic agent. Bio-Path Holdings, Inc. was founded in 2007 ...
Bio-Path Holdings, Inc., a biotechnology company, through its subsidiary, Bio-Path, Inc., develops liposomal drug delivery systems. Its drug delivery technology distributes nucleic acid drugs throughout the human body via intravenous infusion, as well as enables systemic delivery of antisense, small interfering RNA (siRNA), and small molecules for treatment of cancer. The company?s under pre-clinical development products include its lead lipid delivery RNAi drug, BP-100-1.01, that treats acute myeloid leukemia, myelodysplastic syndrome, and chronic myelogenous leukemia; and lead siRNA drug, BP-100-2.01, a targeted ovarian cancer therapeutic agent. Bio-Path Holdings, Inc. was founded in 2007 and is based in Ogden, Utah.
Bio-Path Holdings, Inc., a biotechnology company, through its subsidiary, Bio-Path, Inc., develops liposomal drug delivery systems. Its drug delivery technology distributes nucleic acid drugs throughout the human body via intravenous infusion, as well as enables systemic delivery of antisense, small interfering RNA (siRNA), and small molecules for treatment of cancer. The company?s under pre-clinical development products include its lead lipid delivery RNAi drug, BP-100-1.01, that treats acute myeloid leukemia, myelodysplastic syndrome, and chronic myelogenous leukemia; and lead siRNA drug, BP-100-2.01, a targeted ovarian cancer therapeutic agent. Bio-Path Holdings, Inc. was founded in 2007 ...
USA 
